Differential Coupling of Subtypes of the Muscarinic Receptor to Signaling Mechanisms in Brain and Peripheral Tissues

  • F. J. Ehlert
  • F. M. Delen
  • S. H. Yun
  • P. Tran
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 287)


It has been possible to classify muscarinic receptors on the basis of their specificity for selective muscarinic agents for quite some time. However more recently, considerable progress has been made in characterizing muscarinic receptors, and there is now unequivocal evidence for subtypes of the muscarinic receptor. In this chapter, the relationship between the pharmacological and molecular biological classifications of subtypes of the muscarinic receptor will be discussed briefly, and some recent data on the coupling of subtypes of the muscarinic receptor to adenylate cyclase and phosphoinositide hydrolysis in central and peripheral tissues will also be described.


Adenylate Cyclase Muscarinic Receptor Adenylate Cyclase Activity Corpus Striatum Muscarinic Acetylcholine Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akiba, I., Kubo, T., Maeda, A., Bujo, H., Nakai, J., Mishina, M. and Numa, S., 1988, Primary structure of porcine muscarinic acetylcholine receptor III and antagonist binding studies. FEBS Letts. 235:257–261.CrossRefGoogle Scholar
  2. Birdsall, N.J.M., Hulme, E. C. and Stockton, J. M., 1983, Muscarinic receptor heterogeneity. Trends Pharmacol. Sci. Suppl., pp 4–8.Google Scholar
  3. Bonner, T. I., Buckley, N. J., Young, A. C. and Brann, M. R., 1987, Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527–532.PubMedCrossRefGoogle Scholar
  4. Bonner, T. I., Young, A. C, Brann, M. R. and Buckley, N J., 1988, Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403–410.PubMedCrossRefGoogle Scholar
  5. Brann, M.R., Buckley, N. J. and Bonner, T I., 1988, The striatum and cerebral cortex express different muscarinic receptor mRNA’s. FEBS Letts. 230:90–94.CrossRefGoogle Scholar
  6. Brown, B. R. and Crout, J. R., 1970, The sympathomimetic effect of gallamine on the heart, J. Pharmacol. Ex. Ther. 172:266–273.Google Scholar
  7. Brown, J. H. and Goldstein, D., 1986, Analysis of cardiac muscarinic receptors recognized selectively by nonquaternary but not by quaternary ligands, J. Pharmacol. Ex. Ther.238:580–586.Google Scholar
  8. Buckley, N.J., Bonner, T. I., Buckley, N. J. and Brann, M. R., 1989, Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol. Pharmacol. 35:469–476.PubMedGoogle Scholar
  9. Candell, L. M., Yun, S. H. and Ehlert, F. J., 1990, Differential coupling of subtypes of the muscarinic receptor to adenylate cyclase and phosphoinositide hydrolysis in the longitudinal muscle of the rat ileum, FASEB J. (in press).Google Scholar
  10. Clark, A. L. and Mitchelson, F., 1976, The inhibitory effect of gallamine on muscarinic receptors, Brit. J. Pharmacol. 58:323–331.Google Scholar
  11. Ehlert, F. J., 1988, Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods, Mol. Pharmacol. 33:187–194.Google Scholar
  12. Ehlert, F.J., 1988, Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium, J. Pharmacol. Ex. Ther.247:596–602.Google Scholar
  13. Ehlert, F. J., Delen, F. M., Yun, S. H., Friedman, D. J. and Self, D. W., 1989, Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart, J. Pharmacol. Ex. Ther. 251:660–670.Google Scholar
  14. Ehlert, F. J. and Tran, P., 1989, Regional distribution of binding sites for selective muscarinic antagonists in rat brain, Soc. Neurosci. Abs. 15:229.Google Scholar
  15. Fisher, S. K., 1988, Recognition of muscarinic cholinergic receptors in human SK-N-SH neuroblastoma cells by quaternary and tertiary ligands is dependent upon temperature, cell integrity, and the presence of agonists, Mol. Pharmacol. 33:414–422.Google Scholar
  16. Fisher, S.K. and Bartus, R. T., 1985, Regional differences in the coupling of muscarinic receptors to inositol phospholipid hydrolysis in guinea pig brain, J. Neurochem.45:1085–1095.PubMedCrossRefGoogle Scholar
  17. Franko, B. V., Ward, J. W., Alphin, R. S., 1963, Pharmacological studies of N-benzyl-3-pyrrolidyl acetate methobromide (AHR-602), a ganglion stimulating agent, J. Pharmacol. Exp. Ther. 139:25–30.Google Scholar
  18. Giachetti, A., Micheletti, R. and Montagna, E.,1986, Cardioselective profile of AF-DX 116, a muscarinic M2-receptor antagonist. Life Sci. 38:1663–1672.PubMedCrossRefGoogle Scholar
  19. Gill, E. W. and Rang, H. P., 1966, An alkylating derivative of benzilylcholine with specific and long-lasting parasympatholytic activity, Mol. Pharmacol. 2:284–297.Google Scholar
  20. Gil, D.W. and Wolfe, B. B., 1985, Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase, J. Pharmacol.Ex. Ther. 232:608–616.Google Scholar
  21. Giraldo, E., Hammer, R., and Ladinsky, H., 1987, Distribution of muscarinic receptors subtypes in rat brain as determined in binding studies with AF-DX 116 and pirenzepine, Life Sci. 40:833–840.PubMedCrossRefGoogle Scholar
  22. Giraldo, E., Vigano, M. A., Hammer, R. and Ladinsky, H., 1988a, Characterization of muscarinic receptors in guinea pig ileum longitudinal smooth muscle, J. Pharmacol. Ex. Ther. 33:617–625.Google Scholar
  23. Giraldo, E., Micheletti, R., Montagna, E., Giachetti, A., Vigano, M. A., Ladinsky, H. and Melchiorre, C, 1988a, Binding and functional characterization of the cardioselective muscarinic antagonist methoctramine, J. Pharmacol. Ex. Ther. 244:1016–1020.Google Scholar
  24. Hammer, R., Berrie, C. P., Birdsall, N. J. M., Burgen, A. S. V. and Hulme, E. C., 1980, Pirenzepine distinguishes between different subclasses of muscarinic receptors, Nature183:90–91.CrossRefGoogle Scholar
  25. Hammer, R. and Giachetti, A., 1982, Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 31:2991–2998.PubMedCrossRefGoogle Scholar
  26. Hammer, R., Giraldo, E., Schiavi, G. B., Monferini, E. and Ladinski, H., 1986, Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat. Life Sci. 38:1653–1662.PubMedCrossRefGoogle Scholar
  27. Jones, A., 1963, Ganglionic actions of muscarinic substances, J. Pharmacol. Ex. Ther. 141:195–205.Google Scholar
  28. Kubo, T., Fukuda, K., Mikami, A., Maeda, A., Takahashi, H., Mishina, M., Haga, T., Haga, K., Ichyama, A., Kangawa, K., Kojima, M., Matsuo, H., Hirose, T. and Numa, S., 1986, Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 323:411–416.PubMedCrossRefGoogle Scholar
  29. Lai, J., Mei, L., Roeske, W. R., Chung, F.-Z., Yamamura, H. I. and Venter, J, C., 1988, The cloned murine M1 muscarinic receptor is associated with the hydrolysis of phosphatidylinositols in transfected murine B82 cells. Life Sci. 42:2489–2502.PubMedCrossRefGoogle Scholar
  30. Lambrecht, G., Feifel, R., Forth, B., Strohmann, C., Tacke, R. and Mutschler, E., 1988, p-Fluro-hexahydro-sila-difenidol: The first M2α-selective muscarinic antagonist, Eur. J. Pharmacol. 152:193–194.Google Scholar
  31. Lee J.-H. El-Fakahany, E. E., 1985, Heterogeneity of binding of muscarinic receptor antagonists in rat brain homogenates, J. Pharmacol. Ex. Ther. 233:707–714.Google Scholar
  32. Li, C. K. and Mitchelson, F., 1980, The selective antimuscarinic action of stercuronium, Brit. J. Pharmacol. 70:313–321.Google Scholar
  33. Liao, C.-F., Themmen, A. P. N., Joho, R., Barberis, C., Birnbaumer, M. and Birnbaumer, L., 1989, Molecular cloning and expression of a fifth muscarinic acetylcholine receptor, J. Biol. Chem. 265:7328–7337.Google Scholar
  34. Loffelholz, K., Llndmark, R. and Muscholl, E., 1967, Der Einfluss von atropin auf die noradrenalinfreisetzung durch acetylcholin, Arch. Pharmak. Exp. Path. 257:308.Google Scholar
  35. Maeda, A., Kubo, T., Mishina, M. and Numa, S., 1988, Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes. FEBS Lett. 239:339–342.PubMedCrossRefGoogle Scholar
  36. McKinney, M., Anderson, D., Forray, C. and El-Fakahany, E. E., 1989, Characterization of the striatal M2 muscarinic receptor mediating inhibition of cyclic AMP using selective antagonists: A comparison with the brainstem M2 receptor, J. Pharmacol. Ex. Ther. 250:565–572.Google Scholar
  37. Mei, L, Lai, J., Roeske, W. R., Fraser, C. M., Venter, J. C. and Yamamura, H. I., 1989, Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells. J. Pharmacol. Ex. Ther. 248:661–670.Google Scholar
  38. Nomura, S., Zorn, S. H. and Enna, S. J., 1987, Selective interaction of tricyclic antidepressants with a subclass of rat brain cholinergic muscarinic receptors. Life Sci. 40:1751–1760.PubMedCrossRefGoogle Scholar
  39. Peralta, E. G., Winslow, J. W., Peterson, G. L., Smith, D. H., Ashkenazi, A., Ramachandran, J., Schimerlik, M. H. and Capon, D. J., 1987a, Primary structure and biochemical properties of an M2 muscarinic receptor. Science 236:600–605.PubMedCrossRefGoogle Scholar
  40. Peralta, E. G., Ashkenazi, A., Winslow, J. W., Smith, D. H., Ramachandran, J. and Capon, D. J., 1987b, Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J.6:3923–3929.PubMedGoogle Scholar
  41. Peralta, E.G., Ashkenazi, A., Winslow, J. W., Ramachandran, J. and Capon, D. J., 1988, Differential regulation of PI hydrolysis and adenylate cyclase by muscarinic receptor subtypes. Nature 334:434–437.PubMedCrossRefGoogle Scholar
  42. Rathbun, F.J. and J.T. Hamilton. Effect of gallamine on cholinergic receptors. Can. Anaes. Soc. J. 17:574–590 (1970).CrossRefGoogle Scholar
  43. Riker, W. F. and Wescoe, W. C., 1951, The pharmacology of flaxedil with observations on certain analogs, Ann. N.Y. Acad. Sci. 54:373–394.PubMedCrossRefGoogle Scholar
  44. Roszkowski, A. P., 1961, An unusual type of sympathetic ganglionic stimulant, J. Pharmacol. Ex. Ther. 132:156–170.Google Scholar
  45. Roszkowski, A. P. and Yelnoski, J., 1967, Structure-activity relationships among a series of acetylenic carbamates related to McN-A-343, J. Pharmacol. Ex. Ther. 156:238–245.Google Scholar
  46. Saxena, P. R. and Bonta, I. L., 1970, Mechanism of selective cardiac vagolytic action of pancuronium bromide. Specific blockade of cardiac muscarinic receptors, Eur. J. Pharmacol. 11:332–341.PubMedCrossRefGoogle Scholar
  47. Stockton, J.M., Birdsall, N. J. M., Burgen, A. S. V. and Hulme, E. C., 1983, Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23:551–557.PubMedGoogle Scholar
  48. Waelbroek, M., Gillard, M., Robberecht, P. and Christophe, J., 1987, Muscarinic receptor heterogeneity in rat central nervous system. I. Binding of four selective antagonists to three muscarinic receptor subclasses: A comparison with M2 cardiac muscarinic receptors of the C type. Mol. Pharmacol. 32:91–99.Google Scholar
  49. Walton, F. A., 1950, Flaxedil: A new curarizing agent, Can. Med. Assoc. J. 63:123–129.PubMedGoogle Scholar
  50. Watson, M., Roeske, W. R. and Yamamura, H. I., 1986, [3H]Pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes. J. Pharmacol. Ex. Ther. 237:419–427.Google Scholar
  51. Watson, M., Yamamura, H. I. and Roeske, W. R. 1983, A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes. Life Sci. 32:3001–3011.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • F. J. Ehlert
    • 1
  • F. M. Delen
    • 1
  • S. H. Yun
    • 1
  • P. Tran
    • 1
  1. 1.Department of Pharmacology, College of MedicineUniversity of California, IrvineIrvineUSA

Personalised recommendations